8.2 Peripheral Parenteral Nutrition (PPN) Parameters

8.2 Peripheral Parenteral Nutrition (PPN) Parameters

Clinical Core: Peripheral Parenteral Nutrition (PPN) provides intravenous macronutrient and micronutrient support through peripheral venous access. Because peripheral veins have relatively low blood flow ($20\text{ to } 40\text{ mL/min}$), infusing hypertonic solutions causes endothelial desquamation, sterile inflammation, and thrombophlebitis. PPN is subject to a strict osmolarity ceiling of $\le 900\text{ mOsm/L}$, requiring substantial fluid volumes ($2.5\text{ to } 3.5\text{ L/day}$) to deliver modest nutrition. PPN functions strictly as a short-term clinical bridge ($< 10\text{ to } 14\text{ days}$) and is contraindicated in severe malnutrition and fluid restriction.

Indications, Limitations, and Strict Contraindications

PPN is frequently misunderstood and misused in clinical practice. It is not an interchangeable low-risk substitute for central PN, but rather a highly constrained modality with specific indications and limitations:

Appropriate Clinical Indications

• Short-Term Bridge to Central Access: Providing partial or transitional nutrition support for $3\text{ to } 7\text{ days}$ while awaiting central line placement in a patient unable to tolerate enteral feeding.
• Short-Term Bridge to Enteral Tolerance: Providing supplemental nutrition for $5\text{ to } 10\text{ days}$ during slow advancement of enteral tube feedings following major bowel surgery or resolving paralytic ileus.
• Mild-to-Moderate Nutritional Risk Without Central Access: Patients who require short-term intravenous support ($< 14\text{ days}$) where the insertion risks of a central venous catheter (e.g., severe coagulopathy, severe anatomical distortion) outweigh the benefits of central nutrition.

Clinical Contraindications

1. Severe Fluid Restriction: Patients with oliguric or anuric acute kidney injury, end-stage renal disease (ESRD) not on continuous dialysis, decompensated congestive heart failure (NYHA Class III–IV), or severe hypervolemic hyponatremia. Because PPN solutions must remain dilute to stay $\le 900\text{ mOsm/L}$, delivering even $60\text{ to } 70\text{ g}$ of protein and $1500\text{ kcal}$ requires $2.5\text{ to } 3.5\text{ liters}$ of fluid daily. In fluid-restricted patients, PPN inevitably precipitates pulmonary edema.
2. Severe Malnutrition or High Caloric/Protein Demands: Patients with severe hypercatabolic states (major thermal burns, polytrauma, severe sepsis) or severe preexisting protein-calorie malnutrition cannot achieve their required caloric ($25\text{--}30\text{ kcal/kg/day}$) or protein ($1.5\text{--}2.5\text{ g/kg/day}$) targets within the peripheral osmolarity and fluid volume boundaries. Attempting PPN in severe malnutrition guarantees prolonged underfeeding and muscle proteolysis.
3. Prolonged Duration ($> 10\text{ to } 14\text{ days}$): Peripheral veins undergo rapid progressive sclerosis under the osmolar strain of PPN. Preserving future peripheral venous access dictates transitioning to central venous access if therapy exceeds 10 to 14 days.
4. Compromised Peripheral Venous Access: Patients with a history of intravenous drug use, severe peripheral vascular disease, extensive prior phlebitis, or morbid obesity where peripheral cannulation is difficult or impossible.

---

The $\le 900\text{ mOsm/L}$ Osmolarity Ceiling

The physiological osmolarity of human blood plasma is strictly maintained between $280\text{ and } 295\text{ mOsm/L}$. When a hypertonic solution enters a peripheral vein, a steep trans-endothelial osmotic gradient is generated:

$\Delta \text{Osm} = \text{Osm}_{\text{solution}} - \text{Osm}_{\text{endothelium}}$

PATHOPHYSIOLOGY OF CHEMICAL THROMBOPHLEBITIS

Infusion of Hypertonic PPN (>900 mOsm/L)
                 |
                 v
Rapid Trans-Endothelial Osmotic Fluid Shift (Water pulled out of endothelial cells)
                 |
                 v
Endothelial Dehydration, Cell Shrinkage, & Denudation of Intimal Layer
                 |
                 v
Aseptic Inflammation -> Platelet Adhesion -> Thrombus Formation -> Venous Sclerosis

• Threshold Dynamics: At osmolarities below $600\text{ mOsm/L}$, the incidence of chemical thrombophlebitis is low. As osmolarity rises between $600\text{ and } 900\text{ mOsm/L}$, phlebitis incidence increases linearly. At levels exceeding $900\text{ mOsm/L}$, the incidence of chemical phlebitis, excruciating infusion pain, catheter failure, and secondary extravasation necrosis escalates exponentially. Both ASPEN standards and Infusion Nurses Society (INS) guidelines establish $900\text{ mOsm/L}$ as the absolute safe ceiling for peripheral infusion.

---

Mathematical Estimation of Admixture Osmolarity

In clinical practice and board examinations, calculating the osmolarity of a parenteral formulation requires applying validated conversion factors for each component substrate:

$\text{Total Osmolarity (mOsm/L)} = \frac{\text{Total Milliosmoles (mOsm)}}{\text{Total Formulation Volume (L)}}$

Clinical Conversion Rules of Thumb

• Lipid Emulsion Characteristics: Pure triglycerides have minimal osmotic activity. To stabilize intravenous lipid emulsions, commercial manufacturers incorporate approximately $2.25\%\text{ to } 2.5\%$ anhydrous glycerol ($22.5\text{ to } 25\text{ mg/mL}$) and egg yolk phospholipids ($1.2\%$). The glycerol adjusts the osmolarity of $10\%$, $20\%$, and $30\%$ lipid emulsions to approximately $270\text{ to } 300\text{ mOsm/L}$, making them isotonic with plasma. Consequently, IVLE does not contribute significantly to the chemical osmolar gradient that triggers phlebitis.

---

Worked Step-by-Step PPN Calculations

Case 1: Evaluating a Proposed PPN Formulation

A 58-year-old female (weight $60\text{ kg}$) with postoperative ileus following pelvic surgery is prescribed a 24-hour PPN regimen compounded as a 2-in-1 solution:

• Crystalline Amino Acids: $65\text{ g}$
• Dextrose Monohydrate: $100\text{ g}$
• Sodium Chloride: $60\text{ mEq}$
• Potassium Chloride: $40\text{ mEq}$
• Magnesium Sulfate: $8\text{ mEq}$
• Calcium Gluconate: $9\text{ mEq}$
• Total Fluid Volume: $2200\text{ mL}$ ($2.2\text{ L}$)

Step 1: Calculate Milliosmoles from Macronutrients $\text{mOsm}_{\text{amino acids}} = 65\text{ g} \times 10\text{ mOsm/g} = 650\text{ mOsm}$ $\text{mOsm}_{\text{dextrose}} = 100\text{ g} \times 5\text{ mOsm/g} = 500\text{ mOsm}$

Step 2: Calculate Milliosmoles from Electrolytes $\text{Total Electrolyte mEq} = 60 + 40 + 8 + 9 = 117\text{ mEq}$ $\text{mOsm}_{\text{electrolytes}} = 117\text{ mEq} \times 1.4\text{ mOsm/mEq} = 163.8\text{ mOsm} \quad (\text{or } 117 \times 2 = 234\text{ mOsm})$ (Using the standard $1.4\text{ mOsm/mEq}$ conservative dissociated estimation: $164\text{ mOsm}$)

Step 3: Sum Total Milliosmoles $\text{Total mOsm} = 650 + 500 + 164 = 1314\text{ mOsm}$

Step 4: Calculate Final Solution Osmolarity per Liter $\text{Osmolarity} = \frac{1314\text{ mOsm}}{2.2\text{ L}} = 597.3\text{ mOsm/L}$

• Clinical Judgment: $597\text{ mOsm/L}$ is well below the $900\text{ mOsm/L}$ ceiling. This formulation is safe for peripheral venous infusion.

---

Case 2: Detecting and Correcting an Osmolarity Violation

A resident drafts a concentrated PPN order to restrict volume in an $80\text{ kg}$ patient:

• Amino Acids: $100\text{ g}$
• Dextrose Monohydrate: $200\text{ g}$
• Total Electrolytes: $150\text{ mEq}$ (approx. $250\text{ mOsm}$)
• Total Volume: $1500\text{ mL}$ ($1.5\text{ L}$)

Calculation: $\text{mOsm}_{\text{AA}} = 100 \times 10 = 1000\text{ mOsm}$ $\text{mOsm}_{\text{dextrose}} = 200 \times 5 = 1000\text{ mOsm}$ $\text{mOsm}_{\text{electrolytes}} = 250\text{ mOsm}$ $\text{Total mOsm} = 1000 + 1000 + 250 = 2250\text{ mOsm}$ $\text{Osmolarity} = \frac{2250\text{ mOsm}}{1.5\text{ L}} = 1500\text{ mOsm/L}$

• Clinical Judgment: $1500\text{ mOsm/L}$ grossly exceeds the $900\text{ mOsm/L}$ ceiling. Infusing this solution peripherally will cause rapid, severe chemical phlebitis and vein thrombosis within hours.
• Corrective Redesign: To infuse these macronutrients peripherally, the minimum required volume would be: $\frac{2250\text{ mOsm}}{900\text{ mOsm/L}} = 2.5\text{ L}$. Alternatively, the team must place a central line or reduce the dextrose and amino acid content.

---

Strategies to Minimize Chemical Thrombophlebitis

Maintaining peripheral line patency requires strict adherence to evidence-based nursing, compounding, and delivery practices in this independent study resource:

+-------------------------------------------------------------------------+
|                    STRATEGIES TO MITIGATE PPN PHLEBITIS                 |
+-------------------------------------------------------------------------+
| 1. LIPID BUFFERING: Co-infuse IVLE or compound 3-in-1 TNA admixtures    |
| 2. VEIN SELECTION: Utilize large forearm veins (basilic / cephalic)     |
| 3. AVOID SMALL VEINS: Prohibit infusion into dorsal metacarpal veins    |
| 4. CATHETER GAUGE: Use smallest effective gauge (20G to 22G)            |
| 5. ROTATE SITES: Routine rotation every 72 to 96 hours or upon erythema |
+-------------------------------------------------------------------------+

1. Lipid Buffering (Co-Infusion or 3-in-1 Admixtures):
   • Co-infusing intravenous lipid emulsion via a Y-connector alongside a hypertonic 2-in-1 dextrose-amino acid solution—or compounding the regimen as a single 3-in-1 Total Nutrient Admixture (TNA)—significantly reduces phlebitis.
   • Mechanism: The isotonic lipid emulsion forms a thin, protective hydrophobic coating along the vascular endothelial surface, shielding endothelial cells from direct, concentrated contact with hyperosmolar dextrose and amino acid molecules.
2. Vascular Site Selection:
   • Cannulate large-caliber veins of the forearm: the basilic vein (preferred) or the cephalic vein.
   • Avoid small veins on the dorsum of the hand (metacarpal veins) and veins across the wrist or antecubital fossa. Small veins have low flow rates ($< 15\text{ mL/min}$), magnifying chemical shear stress.
3. Catheter Gauge Selection:
   • Select a small-gauge catheter (20-gauge or 22-gauge) placed into a larger vein. A small catheter allows ample blood flow around the catheter shaft, facilitating immediate dilution of the infusate.
4. Routine Site Rotation:
   • Peripheral IV sites delivering PPN should be rotated every 72 to 96 hours, or immediately upon the earliest signs of tenderness, induration, erythema, or edema.
5. Pharmacologic Additives (Historical vs. Current Practice):
   • Historically, small doses of heparin ($0.5\text{ to } 1.0\text{ unit/mL}$) and/or hydrocortisone ($5\text{ mg/L}$) were added to PPN bags to inhibit microthrombi and suppress local inflammation.
   • Modern practice guidelines discourage the routine addition of heparin or hydrocortisone due to risks of heparin-induced thrombocytopenia (HIT), systemic steroid exposure, and compounding compatibility issues. Proper osmolarity restriction and lipid co-infusion have superseded pharmacologic additives.